Loading..

Zymeworks Inc. (ZYME) Report Analysis

Corporate Events

Negative

Zymeworks Inc. Appoints Dr. Paul Moore as Chief...

2022-06-27 12:30:00

Zymeworks Inc. announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Of...

Neutral

Zymeworks Inc. Presents at 2022 Jefferies Globa...

2022-05-27 09:30:00

Zymeworks Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York...

Neutral

Zymeworks Inc. - Special Call

2022-05-26 21:09:00

To discuss the clinical data presented at ASCO and provide an overview on the clinical development strategy for zanidatamab

Positive

Clinical Data Demonstrating Promising Antitumor...

2022-05-26 21:00:00

Zymeworks Inc. announced new clinical data for the HER2-targeted bispecific antibody zanidatamab in both HER2-positive breast cancer and gastr...

Negative

All Blue Falcons FZE cancelled the acquisition ...

2022-05-20 00:00:00

All Blue Falcons FZE made a non-binding proposal to acquire remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Even...

Negative

Alan Barge Would Serve on Zymeworks Inc.'s Board

2022-05-03 19:27:00

All Blue Capital announced that biopharmaceutical industry leader and expert, Alan Barge, MD, has agreed to advise the firm as Oncology Drug D...

Neutral

Zymeworks Inc. Presents at H.C. Wainwright Glob...

2022-05-02 12:30:00

Zymeworks Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 44...

Positive

Zymeworks Inc. Reports Last Patient Enrolled in...

2022-04-28 12:30:00

Zymeworks Inc. announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activit...

Positive

All Blue Falcons FZE made a non-binding proposa...

2022-04-28 00:00:00

All Blue Falcons FZE made a non-binding proposal to acquire remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Even...

Neutral

Zymeworks Inc. Presents at The 2022 ASCO Annual...

2022-04-27 20:37:00

Zymeworks Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United St...

Neutral

Zymeworks Inc. Presents at PEGS Boston Conferen...

2022-04-23 07:37:00

Zymeworks Inc. Presents at PEGS Boston Conference 2022, May-02-2022 through May-06-2022. Venue: Boston, Massachusetts, United States. Presenta...

Neutral

Zymeworks Inc. Presents at 2022 Fc Receptor and...

2022-04-21 15:29:00

Zymeworks Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United States. ...

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG T...

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, ...

Neutral

Zymeworks Inc. to Report Q1, 2022 Results on Ma...

2022-04-19 20:34:00

Zymeworks Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Zymeworks Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-19 20:34:00

Zymeworks Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Atreca, Inc. Announces Licensing Agreement with...

2022-04-05 20:01:00

Atreca Inc. announced licensing agreement with Zymeworks Inc. to utilize their ZymeLink technology to develop novel antibody-drug conjugates (...

Neutral

Zymeworks Inc. Presents at Bloom Burton & Co. H...

2022-04-01 08:33:00

Zymeworks Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 02:00 PM. Venue: Metro Toronto Convention Centre, 25...

Neutral

Bloom Burton & Co. Inc., Bloom Burton & Co. Hea...

2022-03-31 16:49:00

Bloom Burton & Co. Inc., Bloom Burton & Co. Healthcare Investor Conference, May 02, 2022 through May 03, 2022. Venue: Metro Toronto Convention...

Neutral

Zymeworks Inc. Presents at 12th Annual World AD...

2022-03-30 09:20:00

Zymeworks Inc. Presents at 12th Annual World ADC Conference 2022, Mar-31-2022 03:30 PM. Venue: London, United Kingdom. Speakers: Raffaelle Col...

Neutral

Zymeworks Inc. Presents at Wells Fargo Annual B...

2022-03-29 20:00:00

Zymeworks Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States.

Neutral

Hanson Wade Limited, 12th Annual World ADC Con...

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual...

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Zymeworks Inc. Presents at 4th Annual Guggenhei...

2022-02-03 21:15:00

Zymeworks Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 01:00 PM. Speakers: Kenneth H. Galbraith, President, CEO & Chairman...

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Zymeworks Inc. to Receive Us$8 Million Developm...

2021-12-09 13:37:00

Zymeworks Inc. announced that its collaborator, BeiGene Ltd., has dosed the first patient in South Korea in the HERIZON-GEA-01 trial. As a res...

Positive

Zymeworks Announces Expansion of Zanidatamab Pi...

2021-12-09 13:30:00

Zymeworks Inc. announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON-GEA-01 trial. As a re...

Positive

Zymeworks Inc. Announces New Clinical Data for ...

2021-12-08 23:00:00

Zymeworks Inc. announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast ...

Negative

Zymeworks Inc. Names Neil Josephson as Chief Me...

2021-11-09 21:05:00

Zymeworks Inc. announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer (CMO) since May of thi...

Positive

Zymeworks Inc. and BeiGene, Ltd. Launches Globa...

2021-11-09 13:30:00

Zymeworks Inc. announced, together with its partner BeiGene, the launch of HERIZON-GEA-01. This is a randomized, global Phase 3 study evaluati...

Neutral

Zymeworks Inc. Presents at Stifel 2021 Virtual ...

2021-11-08 21:15:00

Zymeworks Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 01:20 PM. Venue: New York, New York, United States.

Neutral

Zymeworks Inc. Presents at 4th Annual Evercore ...

2021-11-08 21:15:00

Zymeworks Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 03:05 PM.

Neutral

Zymeworks Inc. Presents at 12th Annual Jefferie...

2021-11-08 21:15:00

Zymeworks Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 . Venue: London, United Kingdom.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Zymeworks Inc. - Special Call

2021-10-26 09:32:00

To provide details related to the launch of company's Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, ...

Positive

Zymeworks Inc. Announces Webcast to Present HER...

2021-10-26 09:30:00

Zymeworks Inc. announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first...

Positive

Zymeworks and ALX Oncology Announce First Patie...

2021-10-05 12:30:00

Zymeworks Inc. and ALX Oncology Holdings Inc. announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical tr...

Neutral

Zymeworks Inc. has filed a Shelf Registration.

2021-10-01 00:00:00

Zymeworks Inc. has filed a Shelf Registration. Security Name: Common Shares Security Name: Preferred Shares Security Name: Debt Secur...

Positive

Zymeworks Inc. Announces New Clinical Data for ...

2021-09-16 11:03:00

Zymeworks Inc. announced that new clinical data for zanidatamab, a HER2-targeted bispecific antibody, demonstrate promising response rates and...

Positive

Zymeworks Announces Abstract for Zanidatamab in...

2021-09-12 22:49:00

Zymeworks Inc. announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, i...

Neutral

Zymeworks Inc. - Special Call

2021-09-12 22:49:00

To discuss the updated data

Neutral

Zymeworks Inc. Presents at European Society for...

2021-09-12 22:49:00

Zymeworks Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 08:30 AM. Venue: Paris Expo Porte de Versa...

Neutral

Zymeworks Inc. Presents at Citi’s 16th Annual B...

2021-09-01 05:57:00

Zymeworks Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM. Venue: New York, United States. Speakers: Al...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Zymeworks Inc. Announces Milestone Payment as J...

2021-08-03 20:07:00

Zymeworks Inc. announced that Janssen Biotech Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody developed using ...

Positive

Zymeworks Inc. Announces First Patient with Adv...

2021-07-28 12:35:00

Zymeworks Inc. announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new c...

Neutral

Zymeworks Inc. Presents at Wells Fargo 2021 Vir...

2021-07-22 14:24:00

Zymeworks Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 . Speakers: Ali Tehrani, Co-Founder, President, CEO & D...

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Zymeworks Inc. has filed a Shelf Registration i...

2021-07-09 00:00:00

Zymeworks Inc. has filed a Shelf Registration in the amount of $262.913327 million. Security Name: Common Shares Securities Offered: 7,134...

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Negative

Zymeworks Inc. Appoints Dr. Paul Moore as Chief Scientific Officer, Effective July 18, 2022

2022-06-27 12:30:00

Zymeworks Inc. announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Dr. Moore’s anticipated start date is July 18, 2022. Immediately prior to joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics, heading a team of approximately 50 researchers focused on developing antibody-based therapeutics, including numerous bispecific antibodies and ADCs. During his time at MacroGenics, Paul worked on the development of numerous clinical stage compounds, including retifanlimab (anti-PD-1 mAb), teplizumab (anti-CD3 mAb for Type I diabetes), margetuximab (anti-HER2 mAb), enoblituzumab (anti-B7-H3 mAb), various CD3 based bispecifics including flotetuzumab (CD123 x CD3), bispecifics targeting multiple checkpoints tebotelimab (PD-1xLAG-3) and lorigerlimab (PD-1xCTLA-4), CD32BxCD79B bispecific for autoimmunity and ADC molecules targeting B7-H3 or ADAM-9. Dr. Moore worked on scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Early in his career, he served as Director of Lead Product Development at Human Genome Sciences (HGS), including managing genomic-based target discovery programs that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. In 2012, GlaxoSmithKline (GSK) acquired HGS for $3.6 billion, and GSK reported sales of approximately $0.75 billion for Benlysta during 2021. In 1991, Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents. Dr. Moore’s appointment builds on the Company’s new focus on extending its leadership in the biopharmaceutical industry with a renewed organization and expanding pipeline of product candidates with the potential to make a significant difference for patients around the world with difficult-to-treat cancers. Dr. Moore will be responsible for advancing Zymeworks’ cornerstone multispecific antibody and ADC programs to clinical studies and overseeing the Company’s Early Research and Development Group. Paul’s experience in forming and managing partnerships and collaborations with pharmaceutical companies will be helpful as Zymeworks integrates such partnerships and collaborations into its product development strategy. Zymeworks’ Research Leadership Team consists of four research team leads, reporting to Dr. Moore, in ADC Therapeutic Development Technology and Preclinical Programs, and Multispecific Antibody Therapeutics Technology and Preclinical Programs: Stuart Barnscher, Director, ADC Research: Mr. Barnscher leads the discovery and development of novel ADC technologies and drug candidates with a focus on in vitro and in vivo pharmacology. He was instrumental in the development of the two ADC drug-linker technologies associated with Zymeworks’ ZymeLink™ platform and, since joining Zymeworks in 2016, he has made significant contributions to the design and development of ZW49. Mr. Barnscher obtained his undergraduate degree in biochemistry from the University of British Columbia. Jamie Rich, Ph.D., Director, ADC Research: Dr. Rich focuses on discovery and pipeline applications of new ADC technologies. Since joining Zymeworks in 2016, he has contributed to ZW49, led several pipeline programs, and overseen development of a Topoisomerase 1 inhibitor ADC platform. Dr. Rich is a co-inventor of multiple technologies associated with Zymeworks’ ZymeLink™ platform. He received a Ph.D. from the University of Alberta and held a postdoctoral fellowship at the University of British Columbia. Thomas Spreter Von Kreudenstein, Ph.D., Director, Protein Engineering: Dr. Spreter Von Kreudenstein leads protein engineering and multispecific antibody technologies at Zymeworks. Since joining Zymeworks in 2010, he was one of the lead inventors of Zymeworks’ Azymetric™ technology and has led immune-oncology research programs at the Company, including T-cell engager and cytokine fusion programs. Dr. Spreter Von Kreudenstein received his Ph.D. from the University of Berlin and held a postdoctoral fellowship at the University of British Columbia. Nina Weisser, Ph.D., Director, Multispecific Research: Dr. Weisser leads the development of multispecific antibody therapeutics with a focus on mechanism of action studies. Since joining Zymeworks in 2012, she has led several research programs, including zanidatamab from discovery to early development. Dr. Weisser received her Ph.D. from the University of Guelph and held a post-doctoral fellowship at the National University of Ireland. Oversight of the Company’s research strategy is provided by a committee of the Board of Directors comprised of Dr. Natalie Sacks, Dr. Kenneth Hillan and Dr. Kelvin Neu. The Company also intends to reset the membership of its Scientific Advisory Board in conjunction with the Early Research and Development investor day to be held during the fourth quarter of 2022.

Neutral

Zymeworks Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM

2022-05-27 09:30:00

Zymeworks Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Zymeworks Inc. - Special Call

2022-05-26 21:09:00

To discuss the clinical data presented at ASCO and provide an overview on the clinical development strategy for zanidatamab

Positive

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2-Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

2022-05-26 21:00:00

Zymeworks Inc. announced new clinical data for the HER2-targeted bispecific antibody zanidatamab in both HER2-positive breast cancer and gastric/gastroesophageal junction adenocarcinoma. The data are being presented in two separate poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7, 2022 in Chicago, IL. Over one million patients are diagnosed with gastric cancer every year worldwide, and it is the fourth most common cause of cancer-related deaths. Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 15–25% of gastric cancers. For these patients, trastuzumab in combination with chemotherapy is the global standard of care treatment but with an expected overall survival of less than 18 months, there remains a significant unmet need. In 33 response-evaluable patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma treated with zanidatamab and tislelizumab in combination with the CAPOX chemotherapy regimen the cORR was 75.8% (25/33). The DCR was 100% (33/33) and duration of response (DOR) ranged from 2.1+ to 18.2+ months. Twenty patients (61%) remain on study at the time of data cut-off. In addition, the data demonstrate that zanidatamab and tislelizumab in combination with the CAPOX chemotherapy is generally well tolerated, with the majority of treatment-related adverse events (TRAEs) considered mild to moderate in severity (Grade 1 or 2). The most common grade = 3 TRAE was diarrhea, which was manageable in the outpatient setting; introduction of prophylactic loperamide reduced the incidence from 33% to 21%. Immune mediated adverse events occurred in 27% of patients, including = Grade 3 events in 21% of patients and resulted in discontinuation of tislelizumab in 3 patients (9%). This manageable safety profile compares favorably to the current standard of care as well as to emerging treatments and is consistent with previous reports.

Negative

All Blue Falcons FZE cancelled the acquisition of the remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Eventide Asset Management, LLC and others.

2022-05-20 00:00:00

All Blue Falcons FZE made a non-binding proposal to acquire remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Eventide Asset Management, LLC and others for approximately $570 million on April 28, 2022. All Blue Falcons FZE will pay $10.50 per Share in cash. The All Blue Group has access to sufficient equity capital to finance the proposed acquisition and related fees and expenses. In addition, All Blue has entered into discussions with potential co-investors and financing partners that have expressed interest in providing financing for the proposed acquisition. Accordingly, proposal does not include any financing contingency. The Offer Letter indicates that the Proposal is subject to execution of a definitive transaction agreement and completion of a confirmatory due diligence review of Zymeworks by All Blue Falcons. Blake, Cassels & Graydon LLP and Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisors to Zymeworks Inc. Goodmans LLP and Greenberg Traurig, LLP acted as legal advisors to All Blue Falcons FZE. All Blue Falcons FZE cancelled the acquisition of the remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Eventide Asset Management, LLC and others on May 20, 2022. The Board of Zymeworks unanimously rejects the offer because it substantially undervalues Zymeworks and is not in the best interest of Zymeworks and shareholders. Goldman Sachs & Co. LLC and MTS Health Partners, LP acted as financial advisors to Zymeworks while Kingsdale Advisors acted as strategic shareholder and communications advisor.

Negative

Alan Barge Would Serve on Zymeworks Inc.'s Board

2022-05-03 19:27:00

All Blue Capital announced that biopharmaceutical industry leader and expert, Alan Barge, MD, has agreed to advise the firm as Oncology Drug Development Advisor. In this capacity, Dr. Barge is prepared to provide the expertise, focused leadership and business acumen necessary to support AB's recent proposal to acquire Zymeworks Inc. Following a successful completion of the transaction, Dr. Barge would serve on Zymeworks' board, adding additional value to AB's current offer.Dr. Barge has unmatched expertise in oncology and biopharmaceutical drug development and commercialization. He joined AB after founding Carrick Therapeutics in the UK, which focused on early-stage oncology assets, and co-founding ASLAN Pharmaceuticals, a Singapore-based biopharmaceutical company that focuses on Asia-related cancers. Earlier in his career, Dr. Barge served as Vice President of Clinical and Head of Oncology and Infection at AstraZeneca, where he was responsible for building and managing a large development group and executing AstraZeneca's oncology portfolio globally. He also served as European Medical Director at Amgen.

Neutral

Zymeworks Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-02 12:30:00

Zymeworks Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Positive

Zymeworks Inc. Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of Her2-Expressing Late-Line Biliary Tract Cancer

2022-04-28 12:30:00

Zymeworks Inc. announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancers (BTC), including gallbladder cancer and cholangiocarcinoma (bile duct cancer). Efficacy and safety results from HERIZON-BTC-01 are expected to be announced by early 2023. Biliary tract cancers, including gallbladder cancer and cholangiocarcinoma, account for approximately 3% of all adult cancers and is often associated with a poor prognosis. Globally, more than 210,000 people are diagnosed with BTC every year2 and most patients (> 65%) with BTC are diagnosed with tumors that cannot be removed surgically. The human epidermal growth factor receptor 2 (HER2) is a well-described target for anti-cancer therapy. About 5% to 19% of patients with BTC have tumors that express HER23, suggesting that these patients may have the potential to benefit from HER2-targeted therapy. Currently no HER2-targeted therapy has been approved for the treatment of BTC. HERIZON-BTC-01 is a global, multicenter, open-label, single-arm study with a primary endpoint of confirmed objective response rate (ORR) by independent central review (ICR) per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Secondary endpoints are duration of response (DOR), proportion of subjects with a DOR =16 weeks, disease control rate (DCR), progression-free survival (PFS), overall safety (OS) and safety. HER2 amplification, as determined by in situ hybridization (ISH) in tumor tissue, was an inclusion criterion for all subjects enrolled into the two study cohorts: Cohort 1, the primary efficacy cohort, with tumor tissue showing HER2 immunohistochemistry (IHC) 2+ or 3+ staining, and cohort 2 with tumor tissue showing HER2 IHC 0 or 1+ staining. The study was initiated in July 2020 and has active sites in North America, Asia Pacific, Europe and South America.

Positive

All Blue Falcons FZE made a non-binding proposal to acquire remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Eventide Asset Management, LLC and others for approximately $570 million.

2022-04-28 00:00:00

All Blue Falcons FZE made a non-binding proposal to acquire remaining 93% stake in Zymeworks Inc. (NYSE:ZYME) from Armistice Capital LLC, Eventide Asset Management, LLC and others for approximately $570 million on April 28, 2022. All Blue Falcons FZE will pay $10.50 per Share in cash. The All Blue Group has access to sufficient equity capital to finance the proposed acquisition and related fees and expenses. In addition, All Blue has entered into discussions with potential co-investors and financing partners that have expressed interest in providing financing for the proposed acquisition. Accordingly, proposal does not include any financing contingency. The Offer Letter indicates that the Proposal is subject to execution of a definitive transaction agreement and completion of a confirmatory due diligence review of Zymeworks by All Blue Falcons. Blake, Cassels & Graydon LLP and Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisors to Zymeworks Inc. Goodmans LLP and Greenberg Traurig, LLP acted as legal advisors to All Blue Falcons FZE.

Neutral

Zymeworks Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022

2022-04-27 20:37:00

Zymeworks Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United States. Presentation Date & Speakers: Jun-04-2022, Keun Wook Lee, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Jun-06-2022, Keun Seok Lee, National Cancer Center, Center for Breast Cancer, Goyang, Republic of Korea.

Neutral

Zymeworks Inc. Presents at PEGS Boston Conference 2022, May-02-2022 through May-06-2022

2022-04-23 07:37:00

Zymeworks Inc. Presents at PEGS Boston Conference 2022, May-02-2022 through May-06-2022. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: May-04-2022, Nina E. Weisser, Director, Multispecific Antibody Therapeutics. May-05-2022, Florian Heinkel, Scientist, Protein Engineering.

Neutral

Zymeworks Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022

2022-04-21 15:29:00

Zymeworks Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United States. Speakers: Eric Escobar Cabrera, Cabrera Principal Scientist.

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Zymeworks Inc. to Report Q1, 2022 Results on May 04, 2022

2022-04-19 20:34:00

Zymeworks Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Zymeworks Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-19 20:34:00

Zymeworks Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Atreca, Inc. Announces Licensing Agreement with Zymeworks Inc

2022-04-05 20:01:00

Atreca Inc. announced licensing agreement with Zymeworks Inc. to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate. Atreca management will discuss the agreement, ATRC-301, and its earlier stage pipeline programs during today’s R&D Day beginning at 4:15pm EDT. Zymeworks Agreement: As part of the licensing agreement with Zymeworks, Atreca’s novel antibodies will be conjugated using ZymeLink, Zymeworks’ suite of proprietary cytotoxins, linkers, and conjugation technologies. The agreement includes a two-year research term for Atreca to evaluate antibodies as ADC’s using ZymeLink with the option for a third year, during which Atreca can acquire up to three commercial licenses to develop three unique ADC programs. Work between the two companies has been ongoing since late 2020. ZymeLink is a next-generation drug conjugate platform that provides a suite of proprietary auristatin-based or hemiasterlin-based cytotoxins, complete with stable, cleavable linkers. Antibodies conjugated using the ZymeLink platform have IgG1-like PK & exposure, have demonstrated tolerability and support a wide therapeutic window. ATRC-301: ATRC-301, Atreca’s next clinical candidate, is an ADC that selectively targets a novel, membrane-proximal epitope on erythropoietin-producing hepatocellular receptor A2 (EphA2). EphA2 is a validated and potentially high value target that is widely expressed across several types of cancer, with 12 tumor types displaying prevalence of the target epitope of 50% or greater in human tumor samples evaluated. ATRC-301 has demonstrated potent, dose-dependent in vivo tumor regression in mice with no significant toxicity signals yet observed in rats after single doses of up to and including 30mg/kg. Atreca has initiated IND-enabling studies, including a non-human primate toxicology study for which data are expected in 2H22, and anticipates submitting an IND application for ATRC-301 in 2H23. Atreca also has lead stage CD3-engager targeting EphA2 in development.

Neutral

Zymeworks Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 02:00 PM

2022-04-01 08:33:00

Zymeworks Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 02:00 PM. Venue: Metro Toronto Convention Centre, 255 Front St W, Toronto, Ontario, Canada.

Neutral

Bloom Burton & Co. Inc., Bloom Burton & Co. Healthcare Investor Conference, May 02, 2022 through May 03, 2022

2022-03-31 16:49:00

Bloom Burton & Co. Inc., Bloom Burton & Co. Healthcare Investor Conference, May 02, 2022 through May 03, 2022. Venue: Metro Toronto Convention Centre, 255 Front St W, Toronto, Ontario, Canada. To provide investors the opportunity to hear about the latest developments in the Canadian healthcare industry.

Neutral

Zymeworks Inc. Presents at 12th Annual World ADC Conference 2022, Mar-31-2022 03:30 PM

2022-03-30 09:20:00

Zymeworks Inc. Presents at 12th Annual World ADC Conference 2022, Mar-31-2022 03:30 PM. Venue: London, United Kingdom. Speakers: Raffaelle Colombo, Senior Scientist.

Neutral

Zymeworks Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022

2022-03-29 20:00:00

Zymeworks Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States.

Neutral

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Zymeworks Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 01:00 PM

2022-02-03 21:15:00

Zymeworks Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 01:00 PM. Speakers: Kenneth H. Galbraith, President, CEO & Chairman of the Board.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Zymeworks Inc. to Receive Us$8 Million Development Milestone Payment from Beigene

2021-12-09 13:37:00

Zymeworks Inc. announced that its collaborator, BeiGene Ltd., has dosed the first patient in South Korea in the HERIZON-GEA-01 trial. As a result of this development milestone, Zymeworks will receive a $8 million payment under its zanidatamab collaboration agreement with BeiGene. Zymeworks and BeiGene continue to work to expedite the opening of approximately 300 clinical trial sites across 38 countries in support of the global Phase 3 pivotal trial. With a 24-month projected enrollment period, this study may enable the submission of a supplemental Biologics License Application by Zymeworks in the United States as early as 2024.

Positive

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with Beigene and Associated Milestone Payment

2021-12-09 13:30:00

Zymeworks Inc. announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON-GEA-01 trial. As a result of this development milestone, Zymeworks will receive a USD 8 million payment under its zanidatamab collaboration agreement with BeiGene. Zymeworks and BeiGene continue to work to expedite the opening of approximately 300 clinical trial sites across 38 countries in support of the global Phase 3 pivotal trial. With a 24-month projected enrollment period, this study may enable the submission of a supplemental Biologics License Application by Zymeworks in the United States as early as 2024.

Positive

Zymeworks Inc. Announces New Clinical Data for the HER2-Targeted Bispecific Antibody, Zanidatamab, in Heavily Pretreated HER2-Positive Breast Cancer

2021-12-08 23:00:00

Zymeworks Inc. announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer. The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021. In addition, Zymeworks will present a Trial in Progress poster detailing the ongoing clinical trial evaluating zanidatamab in combination with the CD47-blocker, evorpacept (ALX148). The data presented at SABCS are from a clinical study of 24 patients with heavily pretreated HER2-positive metastatic breast cancer who received zanidatamab in combination with either vinorelbine (n=12), capecitabine (n=8), or paclitaxel (n=4). Patients received multiple prior regimens containing HER2-targeted agents including trastuzumab (96%), pertuzumab (96%), and T-DM1 (96%), and many also received a tyrosine kinase inhibitor. In 22 efficacy-evaluable patients, treatment with zanidatamab and chemotherapy resulted in a cORR of 36.4% and DCR of 86.4%, and the majority of patients experienced a decrease in their tumor size. The mPFS is 7.3 months across all treatment regimens with 42% of patients still on study at the time of data cutoff. Zanidatamab in combination with single agent chemotherapy is well tolerated, with the majority of treatment-related adverse events considered mild to moderate in severity (Grade 1 or 2).

Negative

Zymeworks Inc. Names Neil Josephson as Chief Medical Officer

2021-11-09 21:05:00

Zymeworks Inc. announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer (CMO) since May of this year, will transition to the permanent CMO position, effective November 15. Dr. Josephson joined Zymeworks in 2019 as Vice President, Clinical Research and was promoted to Senior Vice President, Clinical Research last year, before his May appointment to interim CMO. Prior to joining Zymeworks, Dr. Josephson spent nearly six years at Seagen Inc., most recently as Vice President of Clinical Development, where he worked on multiple early and late-stage programs, including leading the approval of ADCETRIS® for the 1st line treatment of advanced Hodgkin’s lymphoma. Before joining Seagen, he was an Associate Professor of Medicine in the Division of Hematology at the University of Washington.

Positive

Zymeworks Inc. and BeiGene, Ltd. Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma

2021-11-09 13:30:00

Zymeworks Inc. announced, together with its partner BeiGene, the launch of HERIZON-GEA-01. This is a randomized, global Phase 3 study evaluating Zymeworks’ investigational HER2-targeted bispecific antibody, zanidatamab, plus chemotherapy, with or without BeiGene’s anti-PD-1-targeted antibody tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for the first-line treatment of metastatic HER2-postive GEA. The primary objective of the HERIZON-GEA-01 study is to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy [CAPOX (capecitabine/oxaliplatin) or FP (5FU/cisplatin)] with or without tislelizumab compared to trastuzumab plus physician’s choice chemotherapy in subjects with advanced or metastatic HER2-positive GEA. Primary endpoints are progression-free survival by RECIST 1.1, assessed by blinded independent central review, and overall survival. The HERIZON-GEA-01 study seeks to enroll approximately 700 patients at approximately 300 sites across 38 countries. BeiGene will oversee trial sites in Asia (excluding Japan), Australia and New Zealand, and Zymeworks will oversee trial sites in the rest of the world, including North and South America, Japan, Europe, Middle East, and Africa. GEA is the fifth most common cancer worldwide and approximately 20% of patients diagnosed with this form of cancer are HER2-positive. HER2-positive GEA has high morbidity and mortality and patients are urgently in need of new treatment options.

Neutral

Zymeworks Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 01:20 PM

2021-11-08 21:15:00

Zymeworks Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 01:20 PM. Venue: New York, New York, United States.

Neutral

Zymeworks Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 03:05 PM

2021-11-08 21:15:00

Zymeworks Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 03:05 PM.

Neutral

Zymeworks Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021

2021-11-08 21:15:00

Zymeworks Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 . Venue: London, United Kingdom.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Zymeworks Inc. - Special Call

2021-10-26 09:32:00

To provide details related to the launch of company's Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers

Positive

Zymeworks Inc. Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers

2021-10-26 09:30:00

Zymeworks Inc. announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers. HERIZON-GEA-01 is a randomized, global Phase 3 study evaluating zanidatamab plus chemotherapy with or without tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for first-line treatment of locally advanced, unresectable, or metastatic HER2-positive GEA.

Positive

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

2021-10-05 12:30:00

Zymeworks Inc. and ALX Oncology Holdings Inc. announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks. The trial is designed to evaluate the safety and efficacy of zanidatamab, Zymeworks’ lead HER2-targeted bispecific antibody, in combination with evorpacept (ALX148), ALX’s CD47 blocker, in patients with advanced HER2-positive breast cancer, HER2-low breast cancer and additional non-breast HER2-expressing solid tumors. This collaboration builds on the promising antitumor activity observed in clinical trials of evorpacept combined with a HER2-targeted antibody in patients with advanced HER2-positive gastric or gastroesophageal junction cancer. The addition of CD47 blockade is designed to enhance zanidatamab’s immunotherapeutic effects and has the potential to provide benefit to a broad population of patients, including those with advanced HER2-expressing breast cancer and potentially other HER2-expressing cancers.

Neutral

Zymeworks Inc. has filed a Shelf Registration.

2021-10-01 00:00:00

Zymeworks Inc. has filed a Shelf Registration. Security Name: Common Shares Security Name: Preferred Shares Security Name: Debt Securities Security Name: Warrants Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Positive

Zymeworks Inc. Announces New Clinical Data for Zanidatamab, A Her2-Targeted Bispecific Antibody, Demonstrate Promising Response Rates and Durability in First-Line Her2- Positive Gea

2021-09-16 11:03:00

Zymeworks Inc. announced that new clinical data for zanidatamab, a HER2-targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2- positive GEA. These data were presented by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESMO Annual Congress. Phase 2 Study Results. The data presented at ESMO are from a clinical study of 36 patients with HER2-expressing GEA who received zanidatamab in combination with either CAPOX (capecitabine/oxaliplatin; n=14), FP (5FU/cisplatin; n=2), or mFOLFOX6 (5FU/leucovorin/oxaliplatin; n=20). None of the patients had received prior HER2-targeted therapies. In 28 response-evaluable patients with metastatic HER2-positive GEA, zanidatamab plus chemotherapy resulted in a cORR of 75% and disease control rate (DCR) of 89% overall, with a cORR of 93% and DCR of 100% in the proposed Phase 3 regimen of zanidatamab + CAPOX/FP. All patients except one experienced a decrease in their tumor size. The mDOR is 16.4 months and the mPFS is 12.0 months across all treatment regimens with 61% of patients still on study at the time of data cutoff. In addition, the data demonstrate that zanidatamab plus chemotherapy is generally well tolerated, with the majority of treatment-related adverse events (TRAEs) considered mild to moderate in severity (Grade 1 or 2). The most common grade = 3 TRAE was diarrhea which was manageable in the outpatient setting; introduction of prophylactic loperamide reduced the incidence in cycle 1 from 44% to 18%. No severe (grade = 3) infusion-related reactions or cardiac events were observed. HER2 is overexpressed in approximately 20% of GEA patients. For these patients, Herceptin® (trastuzumab) is the only approved HER2-targeted therapy in 1L treatment, and therapeutic options are currently limited if disease progression occurs. Zanidatamab’s bispecific approach simultaneously binds two non-overlapping epitopes of HER2, ECD2 and ECD4, resulting in multiple mechanisms of action that provide potential therapeutic benefits beyond the combination of two monoclonal antibodies.

Positive

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

2021-09-12 22:49:00

Zymeworks Inc. announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA. An updated and expanded data set will be presented at the ESMO Annual Congress taking place virtually on September 16-21, 2021. Thirty patients had been treated with zanidatamab in combination with standard of care chemotherapy (either mFOLFOX6, CAPOX, or FP), and 14 patients remained on treatment. The confirmed objective response rate was 68.2% and the disease control rate was 90.9% in 22 HER2-positive response-evaluable patients. Treatment related adverse events were generally consistent with previous reports of zanidatamab and/or the chemotherapy regimens, with the majority reported as Grade 1 or 2 in severity.

Neutral

Zymeworks Inc. - Special Call

2021-09-12 22:49:00

To discuss the updated data

Neutral

Zymeworks Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 08:30 AM

2021-09-12 22:49:00

Zymeworks Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 08:30 AM. Venue: Paris Expo Porte de Versailles, Paris, France.

Neutral

Zymeworks Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM

2021-09-01 05:57:00

Zymeworks Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM. Venue: New York, United States. Speakers: Ali Tehrani, Co-Founder, President, CEO & Director.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Zymeworks Inc. Announces Milestone Payment as Janssen Achieves First Patient Dosed for Its Bispecific Antibody Utilizing Zymeworks' Azymetric and EFECT Therapeutic Platforms

2021-08-03 20:07:00

Zymeworks Inc. announced that Janssen Biotech Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks' Azymetric and EFECT therapeutic platforms. Zymeworks will receive a payment in connection with this milestone under Zymeworks' 2017 licensing agreement with Janssen. Under the terms of that agreement, Zymeworks provided Janssen with a worldwide, royalty-bearing license to research, develop and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks' Azymetric and EFECT platforms. Janssen is responsible for all research, development and commercial activities under the licensing agreement. Zymeworks received an upfront payment of USD 50 million and is eligible to potentially receive up to USD 282 million in development and up to USD 1.12 billion incommercial milestone payments, as well as tiered royalties on potential sales. Janssen also has the option to develop two additional bispecific programs under the agreement subject to a future option payment.

Positive

Zymeworks Inc. Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy

2021-07-28 12:35:00

Zymeworks Inc. announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease. Zanidatamab binds to HER2 across a range of expression levels and has demonstrated multiple mechanisms of action including the formation of receptor clusters, resulting in receptor internalization and downregulation that affect signal transduction. In addition, zanidatamab potently activates the immune system to elicit antibody- dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Tucatinib is a tyrosine kinase inhibitor of HER2 and helps prevent the cancer cells from growing. Several studies have shown that combining agents that target HER2 with complementary mechanisms of action result in proven efficacy. The U.S. Food and Drug Administration last year approved tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can't be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one or more prior treatments.

Neutral

Zymeworks Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021

2021-07-22 14:24:00

Zymeworks Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 . Speakers: Ali Tehrani, Co-Founder, President, CEO & Director, Jack Spinks, Manager, Investor Relations, Ryan Dercho, Senior Director of Corporate Affairs.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Zymeworks Inc. has filed a Shelf Registration in the amount of $262.913327 million.

2021-07-09 00:00:00

Zymeworks Inc. has filed a Shelf Registration in the amount of $262.913327 million. Security Name: Common Shares Securities Offered: 7,134,690 Transaction Features: ESOP Related Offering

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

Zymeworks's financial reports for Q1 showed some underwhelming results. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. As such, Zymeworks received an overall score of 54 and a UNDERPERFORM recommendation.

Zymeworks reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 72.63 million compared to USD 44.59 million a year ago. Basic loss per share from continuing operations was USD 1.18 compared to USD 0.87 a year ago. Diluted loss per share from continuing operations was USD 1.19 compared to USD 0.87 a year ago.

Business Description

Zymeworks, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks was incorporated in 2003 and is headquartered in Vancouver, Canada.

Sector Overview

Zymeworks is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Zymeworks's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 430.0 10.5% 69
Liabilities 147.5 5.4% 77
Price to Book 1.1 -63.0% 43
Cash & Equivalents 275.5 36.5% 90
Equity 282.4 13.4% 70
EBITDA -230.4 -11.9% 53
Total Revenues 28.0 4.8% 58
Parameter Value Change Score
Return on Equity -72.7 -13.1% 77
Net Cashflow -4.4 89.0% 52
Capital Expenditure -15.9 -27.9% 45
Asset Turnover 0.1 5.6% 83
Free Cashflow -4.2 -4.0% 65

* All values are TTM

The below chart reflects Zymeworks's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Zymeworks's peer average final assessment score stands on 63.0, Zymeworks's score is 54.

  •  ZYME
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 0 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 1 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 2 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 3 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 5 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 6 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 7 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 9 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 10 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 11 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 12 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 13 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 14 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 15 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 16 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 18 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 19 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 20 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 21 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 22 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 23 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 25 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 26 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 27 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 28 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 29 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 30 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 31 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 33 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 34 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 36 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 37 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 38 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 39 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 40 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 41 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 42 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 43 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 44 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 45 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 46 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 47 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 48 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 49 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 50 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 51 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 52 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 53 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 54 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 55 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 57 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 58 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 59 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 61 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 62 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 63 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 64 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 65 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 66 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 67 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 68 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 69 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 70 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 71 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 72 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 73 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 74 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 75 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 76 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 77 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 78 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 79 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 80 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 81 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 82 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 84 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 85 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 86 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 87 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 88 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Zymeworks's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Zymeworks's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.

Bearish 42
Close Price 5.62
52W Low 4.82
52W High 37.28
5D MA 6.1
50D MA 5.96
200D MA 13.46
MACD -0.05
RSI 23.52
STOCH 10.74

Balance Sheet Analysis

Cash & Equivalents and Liabilities stood out as the most significant drivers of Zymeworks's balance sheet strength. Zymeworks reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 275.5, representing 36.5% change from the last report. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its cash and cash equivalents movement earned a score of 90. Also, Zymeworks has done an excellent job managing its liabilities. Zymeworks's liabilities stood at 147.5 in the current filing, which represents a 5.4% change from the previous report. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. Therefore, we rated their liabilities movement with a score of 77. On the other hand, Book Value Factors, jumped out as looking rather underwhelming. Zymeworks's price to book ratio (P/B) was reported as 1.1 and represents -63.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Consequently, their book value factors movement received a grade of 43. Therefore, it received a score of 62.

Parameter Value Change Score
Assets 430.0 10.5% 69
Liabilities 147.5 5.4% 77
Price to Book 1.1 -63.0% 43
Cash & Equivalents 275.5 36.5% 90
Equity 282.4 13.4% 70
* All values are TTM

The below chart describes Zymeworks's performance as reflected on its balance sheet with respect to its peers. While Zymeworks received a balance sheet score of 62, the average of its peers stands on 65.0.

  •  ZYME
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 0 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 1 1
Amgen Inc. 130.1B 72 68 86 53 62 69 2 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 3 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 5 1
BioNTech SE 34.0B 75 69 64 97 73 75 6 1
Seagen Inc. 32.9B 59 68 55 43 66 61 7 1
Biogen Inc. 29.7B 57 72 92 50 76 76 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 9 1
Incyte Corporation 16.8B 71 72 95 82 79 83 10 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 11 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 12 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 13 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 14 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 15 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 16 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 17 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 18 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 19 1
Alkermes plc 5.0B 63 66 46 54 71 62 20 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 21 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 22 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 23 1
Natera, Inc. 3.6B 73 65 43 95 42 54 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 25 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 26 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 27 1
CureVac N.V. 2.6B 49 64 75 52 52 57 28 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 29 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 30 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 31 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 33 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 34 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 36 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 37 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 38 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 39 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 40 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 41 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 42 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 43 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 44 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 45 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 46 1
CareDx, Inc 1.2B 54 67 52 39 51 52 47 1
Vericel Corporation 1.1B 51 65 56 53 61 57 48 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 49 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 50 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 51 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 52 1
MannKind Corporation 957.2M 79 59 50 40 64 57 53 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 54 1
Merus N.V. 941.6M 59 68 50 83 81 70 55 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 57 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 58 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 59 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 61 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 62 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 63 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 64 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 65 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 66 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 67 1
Geron Corporation 566.2M 69 72 37 59 62 60 68 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 69 1
Immatics N.V. 538.7M 56 70 84 95 73 76 70 1
Agenus Inc. 520.5M 73 62 37 55 60 54 71 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 72 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 73 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 74 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 75 1
Affimed N.V. 415.0M 56 66 63 56 47 54 76 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 77 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 78 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 79 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 80 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 81 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 82 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 84 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 85 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 86 1
AC Immune SA 299.8M 84 64 47 53 75 68 87 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 88 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

A deep look into Zymeworks's income statement metrics showed some disappointing metrics. The most troubling factors we're looking at are the EBITDA and Revenue Efficiency . Zymeworks's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -230.4, which represents a -11.9% change from the last period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Therefore, their EBITDA component earned a score of 53. Also, Zymeworks management did an underwhelming job managing revenue efficiency this past period. Zymeworks's revenue efficiency is 28.0 according to the metrics in the current filing, which represents a 4.8% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 58. However, one encouraging metric, Return Factors, stood out. Return factors metrics and ratios were exceptional in this report. Zymeworks reported a return on equity (ROE) ratio of -72.7, representing a change of -13.1% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 77. The companie's income statement, therefore, earned a score of 56.

Parameter Value Change Score
EBITDA -230.4 -11.9% 53
Total Revenues 28.0 4.8% 58
Return on Equity -72.7 -13.1% 77
* All values are TTM

The below chart describes Zymeworks's performance as reflected on its income statement with respect to its peers. While Zymeworks received a income statement score of 56 , the average of its peers stands on 63.0.

  •  ZYME
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 91 51 77 66 0 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 1 1
Amgen Inc. 130.1B 74 75 64 78 2 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 3 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 5 1
BioNTech SE 34.0B 41 89 75 79 6 1
Seagen Inc. 32.9B 54 65 70 62 7 1
Biogen Inc. 29.7B 90 57 73 70 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 9 1
Incyte Corporation 16.8B 59 77 60 73 10 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 11 1
United Therapeutics Corporation 10.6B 57 91 54 82 12 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 13 1
Exact Sciences Corporation 7.2B 57 67 54 62 14 1
Exelixis, Inc. 6.7B 54 91 54 81 15 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 16 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 18 1
Ascendis Pharma A/S 5.2B 38 68 46 54 19 1
Alkermes plc 5.0B 69 55 81 62 20 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 21 1
Novavax, Inc. 4.0B 41 89 54 75 22 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 23 1
Natera, Inc. 3.6B 52 51 78 52 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 25 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 26 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 27 1
CureVac N.V. 2.6B 45 83 71 74 28 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 29 1
Insmed Incorporated 2.4B 51 58 73 57 30 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 31 1
Abgenix Inc. 2.1B 47 47 47 47 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 33 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 34 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 36 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 37 1
Xencor, Inc. 1.6B 42 94 52 79 38 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 39 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 40 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 41 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 42 1
Veracyte, Inc. 1.4B 45 63 57 55 43 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 44 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 45 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 46 1
CareDx, Inc 1.2B 61 44 82 50 47 1
Vericel Corporation 1.1B 76 44 82 56 48 1
IVERIC bio, Inc. 1.1B 84 58 79 70 49 1
FibroGen, Inc. 1.0B 48 74 63 67 50 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 51 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 52 1
MannKind Corporation 957.2M 95 48 56 61 53 1
ImmunoGen, Inc. 946.1M 40 73 71 64 54 1
Merus N.V. 941.6M 48 60 59 54 55 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 57 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 58 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 59 1
Amarin Corporation plc 734.5M 95 44 82 63 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 61 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 62 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 63 1
CTI BioPharma Corp. 603.6M 84 50 62 59 64 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 65 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 66 1
AnaptysBio, Inc. 586.3M 97 50 77 68 67 1
Geron Corporation 566.2M 89 67 73 78 68 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 69 1
Immatics N.V. 538.7M 37 93 53 77 70 1
Agenus Inc. 520.5M 57 83 45 74 71 1
Radius Health, Inc. 499.8M 94 71 68 82 72 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 73 1
Vaxart, Inc. 440.0M 99 51 72 68 74 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 75 1
Affimed N.V. 415.0M 95 49 75 66 76 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 77 1
MiMedx Group, Inc. 391.5M 87 43 83 59 78 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 79 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 80 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 81 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 82 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 84 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 85 1
Silence Therapeutics plc 313.4M 83 64 69 72 86 1
AC Immune SA 299.8M 83 61 65 70 87 1
Precigen, Inc. 299.1M 57 87 59 79 88 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Zymeworks's cash flow report highlighted several concerning metrics. Zymeworks's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -15.9, which represents a -27.9% change from the last period. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Consequently, their CapEx movement received a grade of 45. Also, Zymeworks's produced underwhelming cash flow numbers in this filing. Net cash flow was reported as -4.4, which is a 89.0% change from the last report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Zymeworks's stock price going forward. Consequently, their net cash flow movement received a grade of 52. However, one encouraging metric, Asset Turnover, stood out. Zymeworks is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.1, representing a 5.6% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Correspondingly, their asset turnover movement received a grade of 83. Therefore, their cash flow earned a grade of 57.

Parameter Value Change Score
Net Cashflow -4.4 89.0% 52
Capital Expenditure -15.9 -27.9% 45
Asset Turnover 0.1 5.6% 83
Free Cashflow -4.2 -4.0% 65
* All values are TTM

The below chart describes Zymeworks's performance as reflected on its cash flow with respect to its peers. While Zymeworks received a cash flow score of 57, the average of its peers stands on 64.0.

  •  ZYME
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 0 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 1 1
Amgen Inc. 130.1B 80 74 67 74 81 2 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 3 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 5 1
BioNTech SE 34.0B 73 97 50 52 72 6 1
Seagen Inc. 32.9B 53 53 50 87 58 7 1
Biogen Inc. 29.7B 58 54 90 73 66 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 9 1
Incyte Corporation 16.8B 78 79 92 74 84 10 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 11 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 12 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 13 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 14 1
Exelixis, Inc. 6.7B 79 90 89 83 87 15 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 16 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 17 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 18 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 19 1
Alkermes plc 5.0B 89 95 76 80 92 20 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 21 1
Novavax, Inc. 4.0B 62 38 63 54 60 22 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 23 1
Natera, Inc. 3.6B 52 54 56 84 58 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 25 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 26 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 27 1
CureVac N.V. 2.6B 87 80 90 70 90 28 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 29 1
Insmed Incorporated 2.4B 79 80 61 89 82 30 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 31 1
Abgenix Inc. 2.1B 66 53 45 59 58 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 33 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 34 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 36 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 37 1
Xencor, Inc. 1.6B 96 95 70 95 98 38 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 39 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 40 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 41 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 42 1
Veracyte, Inc. 1.4B 90 95 46 46 82 43 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 44 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 45 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 46 1
CareDx, Inc 1.2B 98 84 40 50 86 47 1
Vericel Corporation 1.1B 64 46 59 73 65 48 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 49 1
FibroGen, Inc. 1.0B 86 74 48 87 84 50 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 51 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 52 1
MannKind Corporation 957.2M 77 56 43 37 66 53 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 54 1
Merus N.V. 941.6M 70 71 74 53 71 55 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 57 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 58 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 59 1
Amarin Corporation plc 734.5M 52 40 74 55 55 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 61 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 62 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 63 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 64 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 65 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 66 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 67 1
Geron Corporation 566.2M 78 68 49 81 77 68 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 69 1
Immatics N.V. 538.7M 82 95 56 99 86 70 1
Agenus Inc. 520.5M 57 43 52 77 58 71 1
Radius Health, Inc. 499.8M 64 40 37 56 57 72 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 73 1
Vaxart, Inc. 440.0M 72 56 53 38 65 74 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 75 1
Affimed N.V. 415.0M 72 57 95 43 74 76 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 77 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 78 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 79 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 80 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 81 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 82 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 84 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 85 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 86 1
AC Immune SA 299.8M 66 77 79 63 68 87 1
Precigen, Inc. 299.1M 82 75 37 85 74 88 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.